Chief Medical Officer
Dr. Blank received his medical degree from Universitaet Marburg, Germany. He is board-certified in Germany in internal medicine.
Burkhard Blank, M.D. has been Chief Medical Officer (CMO) at Acorda since July 2016. In January 2016, Dr. Blank was engaged by the Company to assume chief medical officer responsibilities on an interim basis. Dr. Blank’s primary responsibilities include: setting strategy for and execution of development programs from clinical trials through regulatory filings; oversight of post-marketing studies for approved products; and management of the Company’s medical affairs, clinical operations, regulatory affairs, drug safety and biostatistics departments. Dr. Blank has more than 25 years of industry experience, and previously served as CMO for several biopharmaceutical companies, including Boehringer Ingelheim (BI). While at BI, he oversaw the submission of five New Drug Applications (NDAs) and had direct responsibility for all aspects of presenting at two U.S. Food and Drug Administration (FDA) Advisory Committee Meetings; subsequently, all five NDAs received FDA approval. Dr. Blank has also served as a strategic advisor to several biotechnology companies, leading the submission process for multiple Investigational Drug Applications (INDs), successfully developing protocols for clinical trial programs, and overseeing communications with regulatory agencies.